Brief: Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202
05/06/2025 12:22
Regenxbio Inc RGNX.O: REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 REGENXBIO INC - FAVORABLE SAFETY PROFILE CONTINUES WITH NO SERIOUS ADVERSE EVENTS OBSERVED IN RGX-202 TRIAL REGENXBIO INC - PIVOTAL TRIAL EXPECTED TO SUPPORT BLA SUBMISSION USING ACCELERATED APPROVAL PATHWAY IN MID-2026 REGENXBIO INC -EXPECTS TO SHARE TOP-LINE DATA IN FIRST HALF OF 2026 Source text: ID:nPn9bZDbfa Further company coverage: RGNX.O
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics